QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: simple structural fragments as potential modulators of activity

References

• Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737–16740.
   PubMed Web of Science ®Google Scholar
• Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–2696.
   PubMed Web of Science ®Google Scholar
• Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384–7388.
   PubMed Web of Science ®Google Scholar
• Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866–12872.
   PubMed Web of Science ®Google Scholar
• Vane J. Towards a better aspirin. Nature 1994;367:215–216.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228–3232.
   PubMed Web of Science ®Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97–120.
   PubMed Web of Science ®Google Scholar
• Garavito RM, DeWitt DL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1999;1441:278–287.
   PubMed Web of Science ®Google Scholar
• Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W et al. The discovery of rofecoxib [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773–1778.
   PubMed Web of Science ®Google Scholar
• Merck & Co. Press Release; 30 September 2004. http://www.merck.com
   Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954–959.
   PubMed Web of Science ®Google Scholar
• Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–1756.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. Rev Med Liege 2004;59:565–569.
   PubMedGoogle Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–1711.
   PubMed Web of Science ®Google Scholar
• Lagakos SW. Time-to-event analyses for long-term treatments—the APPROVe trial. N Engl J Med 2006;355:113–117.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347–1365.
   PubMed Web of Science ®Google Scholar
• Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43:775–777.
   PubMed Web of Science ®Google Scholar
• Ormrod D, Wellington K, Wagstaff AJ. Valdecoxib. Drugs 2002;62:2059–2071; discussion 2072.
   PubMed Web of Science ®Google Scholar
• Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998;8:2777–2782.
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558–566.
   PubMed Web of Science ®Google Scholar
• Davies IW, Marcoux JF, Corley EG, Journet M, Cai DW, Palucki M et al. A practical synthesis of a COX-2-specific inhibitor. J Org Chem 2000;65:8415–8420.
   PubMed Web of Science ®Google Scholar
• Paul AD, Shah E, Richard MM, Peter J. Lessons from the withdrawal of rofecoxib: patients would be safer if drug companies disclosed adverse events before licensing. Br Med J 2004;329:867–868.
   Google Scholar
• FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879–890.
   PubMed Web of Science ®Google Scholar
• Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004;7:332–336.
   PubMed Web of Science ®Google Scholar
• Chung S, Lim ML, Shin SS. Profiles of COX-2 inhibitors: present and future. Expert Opin Ther Patents 2005;15:9–32.
   Web of Science ®Google Scholar
• Dogné JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem 2005;48:2251–2257.
   PubMed Web of Science ®Google Scholar
• Dogné JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 2006;12:971–975.
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4–15.
   PubMed Web of Science ®Google Scholar
• Sohn HY, Krötz F. Cyclooxygenase inhibition and atherothrombosis. Curr Drug Targets 2006;7:1275–1284.
   Google Scholar
• Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2006;5:83–94.
   PubMed Web of Science ®Google Scholar
• Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J 2006;36:308–319.
   PubMed Web of Science ®Google Scholar
• Orjales A, Mosquera R, López B, Olivera R, Labeaga L, Núñez MT. Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorg Med Chem 2008;16:2183–2199.
   PubMed Web of Science ®Google Scholar
• Shah UA, Deokar HS, Kadam SS, Kulkarni VM. Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors. Mol Divers 2010;14:559–568.
   PubMed Web of Science ®Google Scholar
• Khare A, Trivedi S, Rajak H, Pawar RS, Patil UK, Singour PK. Hansch analysis of novel pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Med Chem Res. DOI: 10.1007/s00044-011–9566-8.
   Google Scholar
• Todeschini R, Consonni V. Dragon Software (version 1.11–2001). Milano, Italy.
   Google Scholar
• Chemdraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA.
   Google Scholar
• Prabhakar YS. A combinatorial approach to the variable selection in multiple linear regression: analysis of Selwood et al. Data Set—a case study. QSAR Comb Sci 2003;22:583–595.
   Google Scholar
• Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978;20:397–405.
   Web of Science ®Google Scholar
• Kettaneh N, Berglund A, Wold S. PCA and PLS with very large data sets. Comput Stat Data Anal 2005;48:69–85.
   Web of Science ®Google Scholar
• Stahle L, Wold S. Multivariate data analysis and experimental design, In: Ellis GP, West WB, eds. Biomedical Research, Progress in Medicinal Chemistry. Elsevier Science Publishers, BV,vol. 25, 1998, pp. 291–338.
   Google Scholar
• So SS, Karplus M. Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations. J Med Chem 1997;40:4347–4359.
   PubMed Web of Science ®Google Scholar
• Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB. CP-MLR/PLS directed structure–activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb Sci 2004;23:234–244.
   Google Scholar
• Gramatica P. Principles of QSAR models validation: internal and external. QSAR Comb Sci 2007;26:694–701.
   Google Scholar
• Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002;20:269–276.
   PubMed Web of Science ®Google Scholar
• Tropsha A, Golbraikh A. UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (personal communication), 2011.
   Google Scholar
• Sachs L. Applied Statistics. A Handbook of Techniques. Springer-Verlag, Berlin, 1982.
   Google Scholar
• Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302–313.
   Google Scholar
• Pratim Roy P, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14:1660–1701.
   PubMed Web of Science ®Google Scholar
• Mitra I, Saha A, Roy K. Exploring quantitative structure–activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Mol Simulat 2010;36:1067–1079.
   Web of Science ®Google Scholar
• Hawkins DM, Basak SC, Mills D. Assessing model fit by cross-validation. j Chem Inf Comput Sci 2003;43:579–586.
   PubMedGoogle Scholar
• Gupta MK, Prabhakar YS. Topological descriptors in modeling the antimalarial activity of 4-(3′,5′-disubstituted anilino)quinolines. J Chem Inf Model 2006;46:93–102.
   PubMed Web of Science ®Google Scholar